Publication
Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerGastrointestinal Stromal Tumorcivic_curation1.00
- drugCrenolanibcivic_curation1.00
- genePDGFRAcivic_curation1.00
- variantPDGFRA D842Icivic_curation1.00
- variantPDGFRA D842_I843delinsVMcivic_curation1.00
- variantPDGFRA D842Vcivic_curation1.00
- variantPDGFRA D842Ycivic_curation1.00
- variantPDGFRA I843DELcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22745105
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PDGFRA D842I1 | ||||||||
| Crenolanib | Gastrointestinal Stromal Tumor | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID43In CHO cells with PDGFRA D842I mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib. PMID 22745105 · Heinrich et al., 2012 · Open in CIViC | civic |
| PDGFRA D842_I843delinsVM1 | ||||||||
| Crenolanib | Gastrointestinal Stromal Tumor | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID47In CHO cells with PDGFRA DI842-843VM mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib. PMID 22745105 · Heinrich et al., 2012 · Open in CIViC | civic |
| PDGFRA D842V1 | ||||||||
| Crenolanib | Gastrointestinal Stromal Tumor | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID44In CHO cells with PDGFRA D842V mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib. PMID 22745105 · Heinrich et al., 2012 · Open in CIViC | civic |
| PDGFRA D842Y1 | ||||||||
| Crenolanib | Gastrointestinal Stromal Tumor | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID45In CHO cells with PDGFRA D842Y mutation that have shown imatinib resistance, crenolanib was significantly more potent at inhibiting kinase activity than imatinib. PMID 22745105 · Heinrich et al., 2012 · Open in CIViC | civic |
| PDGFRA I843DEL1 | ||||||||
| Crenolanib | Gastrointestinal Stromal Tumor | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID46In CHO cells with the PDGFRA deletion I843 mutation that have shown imatinib sensitivity, crenolanib showed no significant difference from imatinib in kinase activity inhibition. PMID 22745105 · Heinrich et al., 2012 · Open in CIViC | civic |